© 2020 © 2020 Genprex Inc. All Rights Reserved.
Note: When you click on media articles below, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.
Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.
Oncoprex in combination with Tagrisso received fast track designation from the Food and Drug Administration to treat patients with non-small cell lung cancer.
The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib (Tagrisso) for the treatment of patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after treatment with osimertinib alone, according to a press release from Genprex, Inc, developer of the therapeutic.
Five companies in the past week reported more than $54 million in funding deals and securities offerings.
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual.
How gene therapy is reprogramming the course of lung cancer.
Lead product, Oncoprex, is an injectable treatment for lung cancer.
SPORE Grants Turn Into Hope for Patients.